You are here
Nicole C. Schmitt, M.D.
Dr. Schmitt received a B.S. in biological sciences at the University of Nevada, Las Vegas, and an M.D. from Washington University in St. Louis. She completed a residency in otolaryngology–head and neck surgery at the University of Washington in Seattle, including two years of full-time research training with T32 and F32 National Research Service Award (NRSA) funding. During this time, Dr. Schmitt studied toxicities of cisplatin chemotherapy in the mouse inner ear and kidney in the laboratory of Dr. Edwin Rubel. Dr. Schmitt then completed a clinical and research fellowship in head and neck surgical oncology and tumor biology at the University of Pittsburgh, studying mechanisms of cisplatin- and cetuximab-induced tumor cell death in the laboratory of Dr. Robert Ferris.
Dr. Schmitt holds a faculty appointment as assistant professor in the Department of Otolaryngology–Head and Neck Surgery at Johns Hopkins University, with an active clinical practice in Bethesda, Maryland, focusing on head and neck oncology, endocrine surgery, and surgery for sleep apnea. She joined the NIDCD as an investigator in the Otolaryngology Surgeon-Scientist Program in the fall of 2015.
Otolaryngology Surgeon-Scientist Program
Novel combination therapies for head and neck cancer; optimizing use of cisplatin chemotherapy for treatment of head and neck squamous cell carcinoma; characterizing and preventing cisplatin-induced hearing loss in head and neck cancer patients; precision medicine for salivary duct carcinoma and other salivary tumors.
- Xiao R, Allen CT, Tran L, Patel P, Park SJ, Chen Z, Van Waes C, Schmitt NC. Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer. Oncoimmunology 2018; doi: 10.1080/2162402X.2018.1471440.
- Spielbauer K, Cunningham L, Schmitt N. PD-1 inhibition minimally impacts cisplatin-induced toxicities in a murine model. Otolaryngol – Head and Neck Surg 2018 Aug;159(2):343-346. doi: 10.1177/0194599818767621. Epub 2018 Apr 3.
- Tran L, Allen CT, Xiao R, Moore E, Davis R, Park SJ, Spielbauer K, Van Waes C, Schmitt NC. Cisplatin alters anti-tumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma. Cancer Immunol Res 2017;5:1141-1151.
- Gilbert MR, Sharma A, Schmitt NC, Johnson JT, Ferris RL, Duvvuri U, Kim S. A 20-year review of 75 cases of salivary duct carcinoma. JAMA Otolaryngol Head Neck Surg. 2016 May 1;142(5):489-95. doi: 10.1001/jamaoto.2015.3930.
- Schmitt NC, Sharma A, Gilbert MR, Kim S. Early T stage salivary duct carcinoma: Outcomes and implications for patient counseling. Otolaryngol Head Neck Surg 2015; pii: 0194599815601659.
- Schmitt NC, Ferris RL. STAT1 activation is enhanced by cisplatin and variably affected by EGFR inhibition in HNSCC cells. Mol Cancer Ther 2015; pii: molcanther.0305.2015.
- Schmitt NC, Rubel EW, Nathanson NM. Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate. J Neurosci 2009; 29:3843–3851.